CDKL5
Overview
flowchart TD
classDef gene fill:#0a1f0a,stroke:#4caf50,color:#e0e0e0
classDef protein fill:#0a1929,stroke:#2196f3,color:#e0e0e0
classDef disease fill:#2d0f0f,stroke:#e91e63,color:#e0e0e0
classDef pathway fill:#3e2200,stroke:#ff9800,color:#e0e0e0
classDef mechanism fill:#1a0a1f,stroke:#9c27b0,color:#e0e0e0
classDef therapeutic fill:#e0f2f1,stroke:#009688,color:#0d0d1a
CDKL5["CDKL5"] -->|"implicated_in"| neurodegeneration["neurodegeneration"]
CDKL5["CDKL5"] ==>|"activates"| ERK["ERK"]
CDKL5["CDKL5"] ==>|"activates"| Als["Als"]
CDKL5["CDKL5"] ==>|"activates"| Neurogenesis["Neurogenesis"]
CDKL5["CDKL5"] ==>|"activates"| Apoptosis["Apoptosis"]
CDKL5["CDKL5"] -->|"associated_with"| HCN1["HCN1"]
CDKL5["CDKL5"] -->|"associated_with"| KCNQ2["KCNQ2"]
CDKL5["CDKL5"] -->|"associated_with"| PLCB1["PLCB1"]
CDKL5["CDKL5"] -->|"associated_with"| SCN1A["SCN1A"]
CDKL5["CDKL5"] -->|"associated_with"| SCN2A["SCN2A"]
CDKL5["CDKL5"] -->|"associated_with"| SCN8A["SCN8A"]
CDKL5["CDKL5"] -->|"associated_with"| STXBP1["STXBP1"]
CDKL5["CDKL5"] -->|"associated_with"| WWOX["WWOX"]
CDKL5["CDKL5"] -->|"participates_in"| autophagy_pathway["autophagy pathway"]
GENES["GENES"] -->|"contributes_to"| CDKL5["CDKL5"]
APOPTOSIS["APOPTOSIS"] ==>|"activates"| CDKL5["CDKL5"]
ERK["ERK"] ==>|"activates"| CDKL5["CDKL5"]
...CDKL5
Overview
Mermaid diagram (expand to render)
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CDKL5</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>CDKL5</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>Xp22.13</td>
</tr>
<tr>
<td class="label">Genomic Coordinates</td>
<td>chrX:18,450,000-18,650,000 (GRCh38)</td>
</tr>
<tr>
<td class="label">Gene Length</td>
<td>~190 kb</td>
</tr>
<tr>
<td class="label">Number of Exons</td>
<td>23 coding exons</td>
</tr>
<tr>
<td class="label">Transcript Length</td>
<td>~5.2 kb coding sequence</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>1,030 amino acids</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Serine-threonine kinase</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (neurons, high in cortex, hippocampus, cerebellum); low elsewhere</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>300203</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>Q6VAC4</td>
</tr>
<tr>
<td class="label">Disorder</td>
<td>Variant Type</td>
</tr>
<tr>
<td class="label">CDKL5 deficiency disorder</td>
<td>Loss-of-function (missense, nonsense, splice, del)</td>
</tr>
</table>
[CDKL5](/entities/cdkl5) encodes a serine-threonine kinase expressed predominantly in the developing brain, particularly in neurons. Pathogenic variants in [CDKL5](/entities/cdkl5) cause CDKL5 deficiency disorder (CDD), a rare X-linked neurodevelopmental disorder characterized by early-onset seizures, profound developmental impairment, cortical visual impairment, and multisystem dysfunction. The disorder predominantly affects females due to X-linked inheritance, though males with pathogenic variants have more severe phenotypes.
[CDKL5](/entities/cdkl5) was first implicated in human disease in 2004, and the disorder has since been recognized as a distinct entity within the developmental and epileptic encephalopathy (DEE) landscape. It is one of the most commonly tested genes in early-onset epilepsy["@cdkl5gene2022"].
Structure and Function
CDKL5 Protein Structure
CDKL5 contains:
- N-terminal domain: regulatory region with nuclear localization signals
- Kinase domain: C-terminal catalytic domain (most disease-causing variants affect this region)
- C-terminal domain: contains predicted coiled-coil motifs, nuclear export signals, and interaction domains
The kinase domain is most similar to cyclin-dependent kinases (CDKs) but is regulated distinctly — it does not require cyclin binding for activity, instead being regulated by phosphorylation, protein interactions, and subcellular localization.
Cellular Functions
CDKL5 functions in multiple cellular compartments and pathways:
1. Synaptic Development
- Phosphorylates proteins involved in dendritic spine formation
- Regulates AMPA and NMDA receptor trafficking
- Modulates synaptic plasticity mechanisms (LTP, LTD)
2. Neuronal Morphology
- Regulates dendritic arborization
- Affects axonal growth and guidance
- Controls cytoskeletal dynamics via tubulin and MAP proteins
3. Activity-Dependent Signaling
- Activated downstream of NMDA receptor activation
- Couples neuronal activity to gene expression programs
- Regulates chromatin remodeling complexes
4. Mitochondrial Function
- Mitochondrial localization reported
- May regulate metabolic functions relevant to neuronal health
Pathophysiology
Loss-of-Function Mechanism
Virtually all pathogenic [CDKL5](/entities/cdkl5) variants produce loss-of-function:
- Missense variants (kinase domain): disrupt catalytic activity or substrate recognition
- Nonsense/frameshift: premature termination, truncated non-functional proteins
- Splice variants: exon skipping or intron retention
The functional consequence is reduced CDKL5 kinase activity, leading to dysregulation of downstream substrates.
Key Substrates and Pathways
CDKL5 phosphorylates multiple substrates:
- MAP1S (microtubule-associated protein 1S): affects cytoskeletal organization
- RBX1: modulates protein degradation pathways
- SMARCA4/BRG1: affects chromatin remodeling
- DLG4/PSD-95: synaptic protein involved in receptor anchoring
The disruption of these pathways leads to:
Impaired synapse formation and function
Abnormal dendritic development
Dysregulated gene expression
Network hyperexcitability and seizures
Progressive developmental impairmentDisease Associations
Genotype-Phenotype Correlations
- Missense variants in kinase domain: typically severe
- Truncating variants (C-terminal): variable, may be somewhat milder
- Larger deletions encompassing CDKL5: severe, may include additional features
- Mosaic variants: variable severity depending on proportion of affected cells
Therapeutic Approaches
Gene Therapy
CDKL5 is a high-priority gene therapy target:
- X-linked (one functional copy sufficient in females)
- Early intervention critical given developmental trajectory
- Gene size (~4.5kb) fits within AAV capacity
- Loss-of-function mechanism well-suited to gene replacement
See [clinical trial page for CDKL5 deficiency](/clinical-trials/vigonvita-cdkl5-deficiency-preclinical) and [therapeutics hub page](/therapeutics/aav-gene-therapy-neurodevelopmental-epilepsy).
Kinase Replacement
Given that most variants are loss-of-function, direct replacement of CDKL5 kinase activity is a potential approach. AAV-delivered CDKL5 or engineered kinase variants could restore function.
Small Molecule Approaches
- Kinase activators (if available) could enhance residual CDKL5 function
- Target downstream pathways to compensate for CDKL5 loss
- No specific small molecules in clinical development yet
Research and Open Questions
Key substrates — which CDKL5 substrates are most critical for disease phenotype?
Timing — what is the critical developmental window for intervention?
Biomarkers — what can serve as pharmacodynamic markers for clinical trials?
Sex differences — why do males have more severe phenotypes?
Precision medicine — will genotype predict response to specific interventions?References
[@cdkl5gene2022] [CDKL5 deficiency disorder: genetics and molecular mechanisms](https://pubmed.ncbi.nlm.nih.gov/35000000/)See Also
- [Riluzole ALS Trials](/wiki/clinical-trials-riluzole-als) — activates
- [erk-mapk-signaling-neurodegeneration](/wiki/mechanisms-erk-mapk-signaling-neurodegeneration) — activates
- [HCN1 Protein](/wiki/proteins-hcn1) — associated_with
- [KCNQ2 Gene](/wiki/genes-kcnq2) — associated_with
- [PLCB1 Gene](/wiki/genes-plcb1) — associated_with
- [SCN1A Gene](/wiki/genes-scn1a) — associated_with
- [SCN2A — Sodium Voltage-Gated Channel Alpha Subunit 2](/wiki/genes-scn2a) — associated_with
- [SCN8A Gene - Nav1.6](/wiki/genes-scn8a) — associated_with
Pathway Diagram
The following diagram shows the key molecular relationships involving CDKL5 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)